IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding
Amir Shanehsazzadeh, Julian Alverio, George W. Kasun, Simon Levine, Ido CalmaniD, Jibran Ahmad KhaniD, Chelsea Chung, Nicolas Diaz, Breanna K. Luton, Ysis Tarter, Cailen M. McCloskey, Katherine B. Bateman, Hayley Carter, Dalton Chapman, Rebecca Consbruck, Alec Jaeger, Christa Kohnert, Gaelin Kopec-Belliveau, John M. SuttoniD, Zheyuan GuoiD, Gustavo Canales, Kai Ejan, Emily Marsh, Alyssa Ruelos, Rylee Ripley, , Sharrol T. BachasiD
Abstract
Deep learning approaches have demonstrated the ability to design protein sequences given backbone structures [1, 2, 3, 4, 5]. While these approaches have been applied in silico to designing antibody complementarity-determining regions (CDRs), they have yet to be validated in vitro for designing antibody binders, which is the true measure of success for antibody design. Here we describe IgDesign, a deep learning method for antibody CDR design, and demonstrate its robustness with successful binder design for 8 therapeutic antigens. The model is tasked with designing heavy chain CDR3 (HCDR3) or all three heavy chain CDRs (HCDR123) using native backbone structures of antibody-antigen complexes, along with the antigen and antibody framework (FWR) sequences as context. For each of the 8 antigens, we design 100 HCDR3s and 100 HCDR123s, scaffold them into the native antibodys variable region, and screen them for binding against the antigen using surface plasmon resonance (SPR). As a baseline, we screen 100 HCDR3s taken from the models training set and paired with the native HCDR1 and HCDR2. We observe that both HCDR3 design and HCDR123 design outperform this HCDR3-only baseline. IgDesign is the first experimentally validated antibody inverse folding model. It can design antibody binders to multiple therapeutic antigens with high success rates and, in some cases, improved affinities over clinically validated reference antibodies. Antibody inverse folding has applications to both de novo antibody design and lead optimization, making IgDesign a valuable tool for accelerating drug development and enabling therapeutic design. The data generated in this study serve as a useful benchmark of diverse antibody-antigen interactions. We use this data to benchmark self-consistency RMSD (scRMSD), using ABodyBuilder2 [6], ABodyBuilder3 [7], and ESMFold [8], as a metric for assessing binding. We open source the code for IgDesign and the SPR datasets. Code and datasets can be found at https://github.com/AbSciBio/igdesign.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 28
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Benchmarking Inverse Folding Models for Antibody CDR Sequence Design
Yifan Li, Yuxiang Lang, … Per Jr Greisen·PLoS ONEPeer-reviewed·Jun 4, 2025
- Antigen-Specific Antibody Design and Optimization with Diffusion-Based Generative Models for Protein Structures
Shitong Luo, Yufeng Su, … Jianzhu Ma·neural information processing systemsPeer-reviewed·Jan 1, 2022
- A Generative Foundation Model for Antibody Design
Rubo Wang, Fandi Wu, … Jianhua Yao·bioRxiv·Sep 12, 2025
- Benchmarking antigen-aware inverse folding methods for antibody design.
Bartosz Janusz, Dawid Chomicz, … Konrad Krawczyk·Bioinformatics AdvancesPeer-reviewed·Jan 1, 2026
- Hallucinating structure-conditioned antibody libraries for target-specific binders
Sai Pooja Mahajan, Jeffrey A. Ruffolo, … Jeffrey J. Gray·Frontiers in ImmunologyPeer-reviewed·Oct 21, 2022
- Antibody Complementarity-Determining Region Sequence Design using AlphaFold2 and Binding Affinity Prediction Model
Takafumi Ueki, Masahito Ohue·Congress in Computer Science, Computer Engineering, and Applied Computing (CSCE)Peer-reviewed·Jul 24, 2023